FY2025 Earnings Forecast for CLDX Issued By Lifesci Capital

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at Lifesci Capital dropped their FY2025 earnings estimates for Celldex Therapeutics in a report released on Monday, November 10th. Lifesci Capital analyst S. Slutsky now anticipates that the biopharmaceutical company will earn ($3.31) per share for the year, down from their prior forecast of ($3.07). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Lifesci Capital also issued estimates for Celldex Therapeutics’ Q4 2025 earnings at ($1.03) EPS.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%.

Several other research analysts have also recently issued reports on the company. Wells Fargo & Company lowered their price objective on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a research report on Wednesday, August 20th. HC Wainwright lowered their price objective on Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a report on Wednesday, August 20th. Barclays cut their price target on shares of Celldex Therapeutics from $25.00 to $21.00 and set an “underweight” rating for the company in a report on Tuesday. Canaccord Genuity Group reiterated a “buy” rating and set a $62.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. Finally, Citigroup lowered their target price on Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.80.

Celldex Therapeutics Trading Down 0.1%

NASDAQ CLDX traded down $0.02 on Thursday, reaching $24.23. 133,419 shares of the company were exchanged, compared to its average volume of 1,015,047. The stock has a market capitalization of $1.61 billion, a P/E ratio of -8.07 and a beta of 1.36. The business’s fifty day moving average price is $25.49 and its 200 day moving average price is $22.82. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $29.05.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Swiss National Bank boosted its position in shares of Celldex Therapeutics by 1.5% during the 3rd quarter. Swiss National Bank now owns 115,800 shares of the biopharmaceutical company’s stock valued at $2,996,000 after acquiring an additional 1,700 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Celldex Therapeutics by 218.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,362 shares of the biopharmaceutical company’s stock worth $190,000 after acquiring an additional 5,047 shares during the period. First Trust Advisors LP purchased a new position in shares of Celldex Therapeutics during the third quarter valued at about $919,000. Propel Bio Management LLC purchased a new stake in Celldex Therapeutics in the 3rd quarter worth about $4,010,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Celldex Therapeutics by 78.7% during the third quarter. Dimensional Fund Advisors LP now owns 257,083 shares of the biopharmaceutical company’s stock worth $6,651,000 after buying an additional 113,197 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.